Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone for COVID-19-associated acute respiratory distress syndrome
2020-001278-31Phase 4Active
- Sponsor
- CIBERES
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexamethasone in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by CIBERES. Primary endpoint: All-cause hospital mortality. Started Apr 2020; status: active.
02
Drugs
dexamethasone
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001278-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001278-31.